articleTop 1% cited
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial
The Lancet Oncology · 2014 · Vol. 15(8) · pp. 852–861
Jonathan A. Ledermann✉(CRUK Lung Cancer Centre of Excellence)Philipp Harter(Kliniken Essen-Mitte)Charlie Gourley(MRC Institute of Genetics and Molecular Medicine)Michael Friedländer(UNSW Sydney)Ignace Vergote(KU Leuven)Gordon Rustin(Mount Vernon Hospital)Clare L. Scott(The Royal Melbourne Hospital)Werner Meier(Evangelisches Krankenhaus Düsseldorf)Ronnie Shapira‐Frommer(Sheba Medical Center)Tamar Safra(Tel Aviv Sourasky Medical Center)Daniela Matei(Indiana University – Purdue University Indianapolis)Anitra Fielding(AstraZeneca (United Kingdom))Stuart Spencer(AstraZeneca (United Kingdom))Brian Dougherty(AstraZeneca (United States))Maria Orr(AstraZeneca (United Kingdom))Darren Hodgson(AstraZeneca (United Kingdom))J. Carl Barrett(AstraZeneca (United States))Ursula A. Matulonis(Dana-Farber Cancer Institute)
PARP inhibition in cancer therapyOvarian cancer diagnosis and treatmentBRCA gene mutations in cancerOlaparibMedicineBRCA mutationOncologyInternal medicineRegimenOvarian cancerPlaceboPopulationCancer
MeSH terms
Poly(ADP-ribose) Polymerase InhibitorsAgedAnemiaAntineoplastic AgentsFatigueFemaleHumansMiddle AgedNeoplasm Recurrence, LocalOvarian NeoplasmsPhthalazinesPiperazinesRetrospective StudiesProportional Hazards ModelsGerm-Line Mutation
Funding
- AstraZeneca
- European Society for Medical Oncology
Citations
1,433
FWCI
74.72
field-weighted impact
References
24
Percentile
100%
vs. same field & year
Citations per year
Cited by
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
The Lancet Oncology · 2017 · 1,842 citations
Targeting the DNA Damage Response in Cancer
Molecular Cell · 2015 · 1,490 citations
ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease
Annals of Oncology · 2019 · 1,130 citations
References
Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities
BMC Cancer · 2008 · 284 citations
Deficiency in the Repair of DNA Damage by Homologous Recombination and Sensitivity to Poly(ADP-Ribose) Polymerase Inhibition
Cancer Research · 2006 · 1,298 citations
Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing
Nature Biotechnology · 2013 · 2,153 citations
MYCN and the epigenome
Frontiers in Oncology · 2013 · 328 citations
Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Annals of Oncology · 2013 · 1,110 citations
Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012
European Journal of Cancer · 2013 · 5,233 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.